← Leaderboards
Asim K Debnath
New York Blood Center
$12,420,611
Attributed
$12,420,611
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2005–23$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$12,420,611 · 5
By mechanism
R01$10,829,907 · 2
R21$813,255 · 2
R56$777,449 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Binding Sites”
- Barton F Haynes · Duke University$271,615,822
- Michael P Snyder · Yale University$102,650,300
- David Heimbrook · Leidos Biomedical Research, Inc.$93,692,184
- Wafaa M. El-Sadr · Columbia University Health Sciences$91,263,426
- Myron S Cohen · Family Health International$91,263,426
- Paul S. Aisen · Cognition Therapeutics, Inc.$72,776,809
Research focus
Binding SitesReportingPharmaceutical PreparationsHiv-1Antiviral AgentsStructureCellsComplexPharmaceutical ChemistryVirusDrug ResistanceDesignBaseAids TherapyInhibitor/AntagonistSmall MoleculeLeadHiv Envelope Protein Gp120PreventAffinityGlycoproteinsDatabasesDockingInfection
Grant awards (21)
Design of inhibitors targeted to the CD4 binding site on HIV - 1gp120$777,449
R56 · FY2023 · AI · contact PI
Design of inhibitors targeted to the CD4 binding site on HIV-1 gp120$850,888
R01 · FY2022 · AI · contact PI
Design of inhibitors targeted to the CD4 binding site on HIV-1 gp120$792,805
R01 · FY2021 · AI · contact PI
Design of inhibitors targeted to the CD4 binding site on HIV-1 gp120$792,805
R01 · FY2020 · AI · contact PI
Design of inhibitors targeted to the CD4 binding site on HIV-1 gp120$867,084
R01 · FY2019 · AI · contact PI
Design of inhibitors targeted to the CD4 binding site on HIV-1 gp120$812,190
R01 · FY2018 · AI · contact PI
Design of inhibitors targeted to the CD4 binding site on HIV-1 gp120$766,762
R01 · FY2017 · AI · contact PI
Design of inhibitors targeted to the CD4 binding site on HIV-1 gp120$768,380
R01 · FY2016 · AI · contact PI
Design of inhibitors targeted to the CD4 binding site on HIV-1 gp120$769,998
R01 · FY2015 · AI · contact PI
Design of inhibitors targeted to the CD4 binding site on HIV-1 gp120$770,397
R01 · FY2014 · AI · contact PI
Design of inhibitors targeted to the CD4 binding site on HIV-1 gp120$744,290
R01 · FY2013 · AI · contact PI
Rational Design of antivrials targeted to HIV-1 capsid$494,502
R01 · FY2013 · AI · contact PI
Rational Design of antivrials targeted to HIV-1 capsid$695,365
R01 · FY2012 · AI · contact PI
Rational Design of antivrials targeted to HIV-1 capsid$528,442
R01 · FY2011 · AI · contact PI
Rational Design of antivrials targeted to HIV-1 capsid$534,400
R01 · FY2010 · AI · contact PI
Rational Design of antivrials targeted to HIV-1 capsid$541,601
R01 · FY2009 · AI · contact PI
Rational Design of antivrials targeted to HIV-1 capsid$99,998
R01 · FY2009 · AI · contact PI
Rational Design of CCR5 Antagonists as Anti-HIV-1 Drugs$205,268
R21 · FY2006 · AI · contact PI
Rational Design of CCR5 Antagonists as Anti-HIV-1 Drugs$207,650
R21 · FY2005 · AI
HIV-1 entry inhibitors targeting Phe43 cavity in gp120$201,663
R21 · FY2003 · AI
HIV-1 entry inhibitors targeting Phe43 cavity in gp120$198,674
R21 · FY2002 · AI